{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:43:48Z","timestamp":1792532628666,"version":"4.5.0"},"reference-count":79,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0079510","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T23:07:27Z","timestamp":1384384047000},"page":"e79510","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":120,"title":["A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson\u2019s Disease"],"prefix":"10.1371","volume":"8","author":[{"given":"Lakkhina","family":"Troeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson\u2019s disease: the quintessential neuropsychiatric disorder","volume":"26","author":"D Weintraub","year":"2011","journal-title":"Mov Disord"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.22760","article-title":"Anxious and depressive symptoms in Parkinson\u2019s disease: the French cross-sectional DoPAMiP study","volume":"25","author":"L Negre-Pages","year":"2010","journal-title":"Mov Disord"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.parkreldis.2007.06.011","article-title":"Anxiety and depression: main determinants of health-related quality of life in Brazilian patients with parkinson\u2019s disease","volume":"14","author":"FJ Carod-Artal","year":"2008","journal-title":"Parkinsonism and Relat D"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicentre study of parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"M Hely","year":"2005","journal-title":"Mov Disord"},{"key":"ref5","first-page":"81","article-title":"Depression in parkinson\u2019s disease: health risks, etiology and treatment options","volume":"4","author":"PG Frisina","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0891988707301866","article-title":"Antidepressant treatment of veterans with Parkinson\u2019s disease and depression: analysis of a national sample","volume":"20","author":"P Chen","year":"2007","journal-title":"J Geriatr Psychiat Neurol"},{"key":"ref7","volume":"12","unstructured":"Hauser RA, Zesiewicz TA (1997) Sertraline for the treatment of depression in Parkinson\u2019s disease. Mov Disord, <volume>12<\/volume>: ; 756\u2013759."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1468-1331.2008.02218.x","article-title":"Motor changes during sertraline treatment in depressed patients with parkinson\u2019s disease","volume":"15","author":"J Kulisevsky","year":"2008","journal-title":"Euro J Neurol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/00207454.2012.726300","article-title":"Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in parkinson\u2019s disease","volume":"123","author":"L Marino","year":"2013","journal-title":"Int J Neurosci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1176\/jnp.16.3.315","article-title":"Citalopram treatment of depression in parkinson\u2019s disease: the impact on anxiety, disability, and cognition","volume":"16","author":"M Menza","year":"2004","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/1531-8257(200009)15:5<986::AID-MDS1034>3.0.CO;2-I","article-title":"Tolerability of paroxetine in parkinson\u2019s disease: a prospective study","volume":"15","author":"S Tesei","year":"2001","journal-title":"Mov Disord"},{"key":"ref12","first-page":"57","article-title":"Efficacy and tolerability of escitalopram for treating depression in parkinson\u2019s disease","volume":"15","author":"R Verma","year":"2012","journal-title":"Delhi Psychiatry J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/jnp.2006.18.3.377","article-title":"Escitalopram for major depression in parkinson\u2019s disease: an open-label flexible dosage study","volume":"18","author":"D Weintraub","year":"2006","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref14","first-page":"201","article-title":"Comparison of sertraline and venlafaxine treatments for depression in Parkinson\u2019s disease","volume":"48","author":"A Alca","year":"2011","journal-title":"Noropsikiyatri Arsivi"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.1980.tb03028.x","article-title":"Anti-depressive treatment in parkinson\u2019s disease: a controlled trial of the effect of Nortriptyline in patients with parkinson\u2019s disease treated with l-dopa","volume":"62","author":"J Andersen","year":"1980","journal-title":"Acta Neurol Scand"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with parkinson\u2019s disease and depression: effect on quality of life","volume":"21","author":"A Antonini","year":"2006","journal-title":"Mov Disord"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson&apos;s disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"D Devos","year":"2008","journal-title":"Mov Disord"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/gps.865","article-title":"SSRIs in the treatment of depression in Parkinson&apos;s disease","volume":"18","author":"AF Leentjens","year":"2003","journal-title":"Int J Geriatr.Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson\u2019s disease and depression","volume":"72","author":"M Menza","year":"2009","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in parkinson\u2019s disease","volume":"78","author":"I Richard","year":"2012","journal-title":"Neurology"},{"key":"ref21","first-page":"1010","article-title":"A comparison between low doses of amitriptyline and low doses of fluoxetine used in the control of depression in patients suffering from parkinson\u2019s disease","volume":"35","author":"M Serrano-Duenas","year":"2002","journal-title":"Rev Neurol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08039489850139049","article-title":"Depression in idiopathic parkinson\u2019s disease treated with citalopram: a placebo-controlled trial","volume":"52","author":"L Wermuth","year":"1988","journal-title":"Nord J Psychiatry"},{"key":"ref23","first-page":"1071","article-title":"Parkinson\u2019s disease combined with depression treated with electroacupuncture and medication and its effect on serum","volume":"32","author":"Y Xia","year":"2012","journal-title":"Chin Acupuncture and Moxibustion"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881113478282","article-title":"Antidepresssants for depression in Parkinson\u2019s disease: systematic review and meta-analysis","volume":"27","author":"FL Rocha","year":"2013","journal-title":"J Psychopharmacol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/09540260020002532","article-title":"Anxiety disorders in parkinson\u2019s disease","volume":"12","author":"L Marsh","year":"2000","journal-title":"Int Rev Psychiatry"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/14656566.3.4.381","article-title":"Drug treatment of non-motor symptoms in parkinson\u2019s disease","volume":"3","author":"T Muller","year":"2002","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jocn.2005.03.008","article-title":"Current approaches to management of depression in parkinson\u2019s disease","volume":"12","author":"FJE Vajda","year":"2005","journal-title":"J Clin Neurosci"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","article-title":"The effect of pramipexole on mood and motivational symptoms in parkinson\u2019s disease: a meta-analysis of placebo-controlled studies","volume":"31","author":"AFG Leentjens","year":"2009","journal-title":"Clin Therapeutics"},{"key":"ref29","first-page":"707","article-title":"Beneficial effect of pramipexole for motor function and depression in parkinson\u2019s disease","volume":"4","author":"O Kano","year":"2008","journal-title":"J Neuro Dis Treat"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jns.2006.05.024","article-title":"Effects of the dopamine agonist pramipexole on depression, anhedonia, and motor functioning in parkinson\u2019s disease","volume":"248","author":"MR Lemke","year":"2006","journal-title":"J Neurol Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1176\/jnp.17.2.214","article-title":"Anhedonia, depression, and motor functioning in parkinson\u2019s disease during treatment with pramipexole","volume":"17","author":"MR Lemke","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in parkinson\u2019s disease: a national multicentre prospective randomized study","volume":"10","author":"I Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"P Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease","volume":"253","author":"P Barone","year":"2006","journal-title":"J Neurol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1212\/01.WNL.0000166038.67153.9F","article-title":"Dietary fatty acids and the risk of Parkinson disease: The Rotterdam study","volume":"54","author":"LML De Lau","year":"2005","journal-title":"Neurology"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.20738","article-title":"Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys","volume":"59","author":"P Samadii","year":"2006","journal-title":"Ann Neurol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","article-title":"Depression in Parkinson\u2019s disease: A double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation","volume":"111","author":"T Moralez Da Silva","year":"2008","journal-title":"J Aff Disord"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/mds.23266","article-title":"Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson\u2019s disease","volume":"25","author":"R Chen","year":"2010","journal-title":"Mov Disord"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.clinph.2007.07.010","article-title":"An open study of repetitive transcranial magnetic stimulation in treatment-resistant depression with Parkinson\u2019s disease","volume":"118","author":"CM Epstein","year":"2007","journal-title":"Clin Neurophys"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/mds.10109","article-title":"Therapeutic efficacy of bilateral prefrontal slow repetitive transcranial magnetic stimulation in depressed patients with Parkinson&apos;s disease: An open study","volume":"17","author":"N Dragasevic","year":"2002","journal-title":"Mov Disord"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/mds.21613","article-title":"Efficacy of rTMS in the treatment of co-morbid anxiety in depressed patients with Parkinson\u2019s disease","volume":"22","author":"TC Kormos","year":"2007","journal-title":"Mov Disord"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/jnnp.2003.027060","article-title":"Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson\u2019s disease","volume":"75","author":"F Fregni","year":"2004","journal-title":"J Neuro Neurosur Psychiat"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1002\/mds.23270","article-title":"The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled study","volume":"25","author":"E Pal","year":"2010","journal-title":"Mov Disord"},{"key":"ref44","volume":"11","unstructured":"Cole K, Vaughan FL (2005) The feasibility of using cognitive behaviour therapy for depression associated with parkinson\u2019s disease: A literature review. Parkinsonism Relat D, <volume>11<\/volume>: : 269 \u2013 276."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Laidlaw K (2008) Cognitive Behaviour Therapy for depression in Parkinson\u2019s disease. In K. Laidlaw &amp; B. Knight (ed\u2019s), Handbook of emotional disorders in later life: Assessment and treatment. NY: Oxford University Press.","DOI":"10.1093\/med:psych\/9780198569459.003.0016"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1176\/appi.psy.47.3.259","article-title":"A cognitive-behavioural treatment package for depression in Parkinson\u2019s disease","volume":"47","author":"RD Dobkin","year":"2006","journal-title":"Psychosom"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/mds.21455","article-title":"Cognitive-behavioural therapy for depression in Parkinson\u2019s disease: A pilot study","volume":"22","author":"RD Dobkin","year":"2007","journal-title":"Mov Disord"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0891988711422529","article-title":"Telephone-based cognitive-behavioural therapy for depression in Parkinson\u2019s disease","volume":"24","author":"RD Dobkin","year":"2011","journal-title":"J Ger Psychiat Neurol"},{"key":"ref49","first-page":"124","article-title":"Cognitive-behavioural therapy for patients with Parkinson\u2019s disease and comorbid major depressive disorder","volume":"51","author":"A Farabaugh","year":"2010","journal-title":"Psychosomatics"},{"key":"ref50","volume":"9","unstructured":"Feeney F, Egan S, Gasson N (2005) Treatment of depression and anxiety in parkinson\u2019s disease: a pilot study using group cognitive behavioural therapy. Clin Psych, <volume>9<\/volume>: : 31 \u2013 38."},{"key":"ref51","volume":"22","unstructured":"Gupta R (2000) Treatment of depression in an elderly Asian Indian male: A cognitive behavioural approach. Clin Gerontol, <volume>22<\/volume>: : 87 \u2013 89."},{"key":"ref52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1077-7229(01)80005-5","article-title":"Cognitive-behavioural treatment for social phobia in Parkinson\u2019s disease: A single-case study","volume":"8","author":"N Heinrichs","year":"2001","journal-title":"Cog Behav Prac"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Laidlaw K, Thompson LW, Siskin-Dick L, Gallagher-Thompson D (2003) Cognitive Behavioural Therapy with Older People. Chichester: John Wiley &amp; Sons, Ltd.","DOI":"10.1002\/9780470713402"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1534650109351305","article-title":"A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson\u2019s disease","volume":"9","author":"J Mohlman","year":"2010","journal-title":"Clin Case Stud"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive behaviour therapy for depression in Parkinson\u2019s diseae: a randomized controlled trial","volume":"168","author":"RD Dobkin","year":"2011","journal-title":"Am J Psychiatry"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2377-10-49","article-title":"Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in parkinson\u2019s disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"P Skapinakis","year":"2010","journal-title":"BMC Neurol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/jnp.7.3.281","article-title":"Treatment of depression in Parkinson\u2019s disease: a meta-analysis","volume":"7","author":"T Klaassen","year":"1995","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.20555","article-title":"Antidepressant studies in Parkinson\u2019s disease: a review and meta-analysis","volume":"20","author":"D Weintraub","year":"2005","journal-title":"Mov Disord"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/00207450701239418","article-title":"The effects of antidepressants in Parkinson\u2019s disease: a meta-analysis","volume":"118","author":"PG Frisina","year":"2008","journal-title":"Int J Neurosci"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S (2008). Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Book Series. Chichester: John Wiley &amp; Sons Ltd.","DOI":"10.1002\/9780470712184"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed effect and random-effects models for meta-analysis","volume":"1","author":"M Borenstein","year":"2010","journal-title":"Res Syn Meth"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update.","volume":"28","author":"R DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"ref64","first-page":"1","article-title":"Weighting by inverse variance or by sample size in random-effects meta-analysis","volume":"1","author":"F Marin-Martinez","year":"2009","journal-title":"Educ Psychol Meas"},{"key":"ref65","unstructured":"Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. Orlando, Florida, Academic Press."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed- and random-effects models in meta-analysis","volume":"3","author":"LV Hedges","year":"1988","journal-title":"Psychol Methods"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis of clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Contemp Clin Trials"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0895-4356(99)00161-4","article-title":"Publication bias in meta-analysis: its causes and consequences","volume":"53","author":"A Thornton","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1037\/0033-2909.86.3.638","article-title":"The \u201cfile drawer problem\u201d and tolerance for null results","volume":"85","author":"R Rosenthal","year":"1979","journal-title":"Psychol Bull"},{"key":"ref71","first-page":"557","article-title":"Measuring inconsistency in meta analyses. BMJ","volume":"327","author":"JPT Higgins","year":"2003"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JPT Higgins","year":"2002","journal-title":"Statist Med"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10880-009-9167-6","article-title":"Telephone-administered cognitive behavioural therapy: a case study of anxiety and depression in Parkinson\u2019s disease","volume":"16","author":"C Veazey","year":"2009","journal-title":"J Clin Psychol Med Settings"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1590\/S0004-282X2009000300007","article-title":"The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson\u2019s disease","volume":"67","author":"ALS Werneck","year":"2009","journal-title":"Arq Neuro-Psiquiatr"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0924-9338(10)70248-0","article-title":"Depression in Parkinson\u2019s disease \u2013 searching for the most potent antidepressant","volume":"25","author":"G Djokic","year":"2010","journal-title":"Eur Psychiatry"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"D Weintraub","year":"2010","journal-title":"Neurology"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/13607860701529635","article-title":"Effects of psychotherapy and other behavioural interventions on clinically depressed older adults: a meta-analysis","volume":"11","author":"M Pinquart","year":"2007","journal-title":"Aging Ment Health"},{"key":"ref78","unstructured":"National Institute of Health and Clinical Excellence (2010) Depression. The NICE Guideline on the Treatment Management of Depression in Adults. Updated Version, Great Britain, British Psychological Society and the Royal College of Psychiatrists."},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1176\/appi.ajp.2011.11071124","article-title":"A new(old) treatment option for depression in Parkinson\u2019s disease","volume":"168","author":"KJ Black","year":"2011","journal-title":"Am J Psychiatry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0079510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T23:44:46Z","timestamp":1540338286000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0079510"}},"subtitle":[],"editor":[{"given":"Xiang Yang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":79,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2013,11,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0079510","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}